Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Launched by ASTRAZENECA · Dec 19, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at the safety of a combination treatment called IMJUDO and IMFINZI, as well as IMFINZI on its own, for patients with a type of liver cancer known as unresectable hepatocellular carcinoma (HCC). The goal is to gather information on how well these treatments work in real-world settings after they have been approved for use.

If you or a loved one has been diagnosed with unresectable HCC and are receiving either the combination therapy or just IMFINZI, you may be eligible to participate in this study. There are no specific age or gender requirements, so all patients receiving these treatments can join. Participants will have the opportunity to contribute to important research while receiving standard care. It’s a great way to help advance our understanding of these therapies and improve treatment options for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients who receive IMJUDO and IMFINZI combination therapy or IMFINZI monotherapy for their unresectable HCC.
• • -
• Exclusion Criteria:
• • -